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Introduction
The number of patients undergoing non-vascular sur-
gery is rising and a remarkable number of these subjects 
experience cardiac events, including cardiac death and 
non-fatal myocardial infarction (MI), or non-fatal car-
diac arrest.1 Although, the value of medical consultation 
in preoperative risk evaluation seems to be imperative, 
investigations have nevertheless questioned the effec-
tiveness of preoperative assessment.2 Therefore, the 
development of an accurate and practical test that will 
provide timely assistance to surgeons, cardiologists, 
anesthesiologists and patients is necessary. Currently, 
the American College of Cardiology/American Heart 
Association (ACC/AHA) Guidelines recommends the 
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implementation of non-invasive testing for preoperative 
risk stratification only for high-risk surgical procedures.3
The application of myocardial perfusion imaging in 
preoperative risk evaluation has been assessed in many 
studies, with controversial results. Although the majority 
of studies demonstrated a positive role,4-9 the outcome of 
myocardial perfusion imaging (MPI) SPECT in the pre-
diction of perioperative cardiac events is not well under-
stood and requires further assessment for its application 
in clinical practice. In addition, some issues, such as the 
type of radiotracer, coronary artery disease (CAD) risk 
factors and type of perfusion defect, as well as the stress 
type of MPI, are not clearly elucidated.
The aim of this study was to evaluate the usefulness of 
dipyridamole technetium-99m sestamibi MPI SPECT 
for the prediction of perioperative cardiac events in 
patients undergoing elective non-vascular surgery. 
Furthermore, the association of cardiac events with some 
clinical parameters was also investigated.
Materials and Methods
Participants and study design
Three hundred and twelve patients were referred for 
preoperative, pharmacologic stress, myocardial perfu-
sion imaging from September 2005 to September 2011. 
Stress testing was carried out within three weeks prior to 
non-vascular surgery requiring general anesthesia.7 
Planned surgery was suspended for 59 patients due to 
high risk prognostic findings observed on MPI, such as 
a large defect size, defects in more than one coronary 
artery supply region, reversible defects in multiple myo-
cardial scan segments, a large number of non-reversible 
defects and transient or persistent left ventricular cavity 
dilation.10 The remaining 253 participants, who gave 
informed consent, were enrolled in the study. None of 
the participants had a history of coronary revascular-
ization (coronary artery bypass grafting (CABG) or 
percutaneous coronary intervention (PCI)), valvular 
heart disease, congestive heart failure (CHF), congeni-
tal heart disease (CHD), cardiomyopathy or serious 
life-threatening illnesses. All patients were candidates 
for elective operations and surgery was carried out in 
the departments of surgery, urology, orthopedics, 
gynecology, neurosurgery and ophthalmology.
Each patient completed a questionnaire, providing 
information on risk factors. We investigated the relation-
ship between clinical risk factors and the occurrence of 
perioperative cardiac events. Clinical factors considered 
included age ≥70 years, sex, hypertension, dyslipidemia, 
diabetes mellitus and smoking. Risk factors encountered 
during the study included: (1) hypertension (self-
reported history of hypertension and/or use of antihy-
pertensive medication or a blood pressure >140/90 
mmHg); (2) smoking and (3) dyslipidemia (high-density 
lipoprotein cholesterol <40 mg/dl, low-density lipopro-
tein cholesterol >100 mg/dl or antihypercholesterolemic 
treatment). Pretest likelihood of coronary artery disease 
(CAD) was estimated by consideration of age, the ratio of 
cholesterol to HDL, gender and smoking.11
The study complies with the Declaration of Helsinki 
and this was confirmed by the institutional ethics com-
mittee of Shahid Beheshti University of Medical 
Sciences.
Perioperative cardiac events
Perioperative cardiac events were assessed during the 
period of surgery and for 72 hours following surgery. 
The clinicians were blinded to the clinical variables and 
scintigraphic data. Events included cardiac death (sud-
den death and death resulting from MI or CHF), non-
fatal MI (distinguished by an increase in cardiac enzymes 
and the progression of either new Q waves or constant 
ST-T wave changes), CHF (presence of pulmonary 
edema sign and symptoms), unstable angina (develop-
ment of ≥2 episodes of ischemic electrocardiographic 
changes with a succeeding resolution), cardiac arrhyth-
mia that necessitated antiarrhythmic drugs and, also, 
severe hypotension requiring inotropic support to main-
tain blood pressure.
Dipyridamole technetium 99m-sestamibi 
SPECT protocol
All subjects underwent a two-day stress SPECT proto-
col. Technetium-99m sestamibi (740 MBq) was intra-
venously infused at rest and during pharmacologic 
stress.
All cardiovascular drugs were stopped for at least two 
days and the patients fasted overnight before the study. 
Intravenous normal saline solution was connected to an 
antecubital vein, using a 20-gauge cannula. Dipyridamole 
(0.56 mg/kg) was administered over four minutes. The 
patients’ symptoms and 12-lead ECG were monitored 
constantly. A dose of 740 MBq of Tc-99m Sestamibi, as a 
compact bolus, was injected four minutes after the start 
of the infusion. Twenty minutes later, the patients were 
asked to eat a fatty meal to accelerate hepatobiliary clear-
ance of Tc-99m sestamibi and imaging was carried out 
90 minutes after the initial infusion of dipyridamole. The 
rest phase was performed the next day.
Acquisition and processing protocols
A double-head SPECT scintillation camera (ADAC 
Genesys, Malpitas, CA, USA) was used to acquire 32 views 
over 180°, using a step-and-shoot method, progressing 
from 45° right anterior oblique to 45° left posterior 
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oblique projections. A symmetric 20% energy window 
over the 140 keV Tc-99m photopeak and a low energy all-
purpose (LEAP) collimator were used and the data were 
stored in 64 x 64 matrices. Acquisition time was 25 sec-
onds per projection during rest and stress studies. An 
expert nuclear medicine specialist used the cine display of 
the rotating planar projections to evaluate sub-diaphrag-
matic activities, attenuations, and patient motion to opti-
mize the quality of the images. Processing was performed 
using a two-dimensional Butterworth prefilter and a 
ramp filter for back projection to transaxial tomographic 
images. The reorientations of images were performed 
along the vertical long axis and the horizontal and short 
axes of the left ventricle. Acquisition parameters were 
similar for the rest and stress studies. For each image, all 
three stress image sets were interpreted discretely in 
comparison with the same rest image.
Visual SPECT analysis
For assessment, MPIs were divided into 17 segments, 
corresponding to the locations of the territories of the 
various coronary arteries. For the assessment of the 
segments, a three-grade scale was used: normal perfu-
sion, and reversible and fixed segments. A reversible 
defect was defined as the presence of a region with 
decreased or absent myocardial activity on stress scans 
which improved in the rest stage images. A fixed seg-
ment was defined as a region of decreased or absent 
myocardial activity in both the stress and rest sets. 
Image interpretation was performed by two nuclear 
medicine specialists without knowledge of the patients’ 
data.
Statistical analysis
A two-tailed t-test was used to compare the mean values 
between the groups. The continuous variables are 
expressed as the mean ± SD and categorical variables as 
the absolute values and percentages. Student’s t-test was 
used to compare differences between continuous vari-
ables and the Chi-square test was used for categorical 
variables. The MPI findings compared to cardiac events 
were categorized as true positive (TP), true negative 
(TN), false positive (FP) or false negative (FN). 
Thereafter, the statistical parameters were determined as 
follows: specificity [TN/(TN+FP)], sensitivity [TP/
(TP+FN)], PPV [TP/(TP+FP)], NPV [TN/(TN+FN)] 
and accuracy [(TP+TN)/(TP+TN+FN+FP)]. Multiple 
logistic regression analysis was applied to evaluate the 
association of cardiac event as a dependent variable with 
other variables, including MPI results, diabetes mellitus 
(DM), hypertension, dyslipidemia, smoking, age and 
gender. The statistical analysis was carried out using the 
Statistical Package for the Social Science (SPSS) version 
18 (SPSS Inc., Chicago, IL, USA). A p<0.05 was consid-
ered to be statistically significant.
Results
A total of 253 patients (169 males and 84 females) with a 
mean age 55.8± 9.43 years were included in the study. 
Thirty (11.8%) patients had diabetes mellitus (DM), 65 
(25.7%) had hypertension, 102 (40.3%) had dyslipidemia 
and 93 (36.7%) were smokers.
The pretest likelihood of CAD was low in 158 patients, 
intermediate in 31 patients, high in five and very high in 
59 patients. Thirteen cardiac events occurred in patients 
in the very high group and one occurred in the high 
group. No cardiac events occurred in patients with low 
or intermediate pretest likelihood of CAD.
Of the total 253 patients, 56 patients (22.1%) had per-
fusion abnormalities in pharmacologic stress myocardial 
perfusion SPECT and the remaining 197 patients (77.9%) 
had no perfusion abnormalities. In 56 patients with 
abnormal MPI, 36 patients (64.3%) had reversible perfu-
sion defects, 12 patients (21.4%) had fixed defects and 
eight patients (14.3%) had both reversible and fixed 
defects.
Perioperative cardiac events occurred in 14 patients 
(5.5%). Six of the 14 patients had ventricular tachycardia 
during surgery and required a continuous administra-
tion of anti-arrhythmic drugs. Three cases had non-fatal 
MIs and two cases died. Two of the patients who died 
from cardiac arrest included a 78-year-old man with a 
history of dyslipidemia and hypertension and a 90-year-
old man with a history of smoking and dyslipidemia.
In addition, three patients exhibited severe hypoten-
sion and required inotropic support to maintain blood 
pressure following surgery.
Five of the 158 patients with low pretest likelihood of 
CAD, three of the 31 patients with intermediate pretest 
likelihood of CAD, two of the five patients with high pre-
test likelihood of CAD and 46 of the 59 patients with 
very high likelihood of CAD had abnormal MPI.
In 14 patients with cardiac events, 12 cases (21.4%) 
had abnormal MPI and the remaining two cases (1.01%) 
had normal MPI. There was a significant difference in 
the number of cardiac events between patients with nor-
mal and abnormal MPI (p<0.001) (Figure 1).
In 12 patients with cardiac events who had abnormal 
MPI, seven cases had both reversible and fixed defects, 
three cases had reversible perfusion defects and two 
patients had fixed defects. The location of the perfusion 
defects was in the inferoapical region in three patients, in 
the apicoseptal region in five patients, in the anterior and 
septal regions in two patients and in the inferior and 
inferolateral regions in two patients.
The sensitivity, specificity and accuracy of MPI for 
predicting perioperative cardiac events were 85.7%, 
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81.6%, and 81.8%, respectively, in all patients operated 
on. The positive predictive value (PPV) and negative 
predictive value (NPV) were 21.4% and 98.9%, respec-
tively, in all patients.
The comparison of various CAD risk factors in 
patients with and without cardiac events showed a sig-
nificant difference (p<0.05) (Table 1). The distribution of 
CAD risk factors also showed a significant difference in 
patients with normal and abnormal MPI (p<0.05) (Table 
2). In addition, comparison of various CAD risk factors 
in patients with abnormal MPI who did and did not have 
cardiac events showed a significant difference in age ≥70 
years (p=0.013) (Table 3).
According to multiple regression analyses with car-
diac event as a dependent variable, the MPI (Odds Ratio 
= 23.118; 95% CI: 1.65- 323.95; p=0.02), diabetes melli-
tus (Odds Ratio = 7.021; 95% CI: 1.49- 33.087; p=0.01) 
and age (Odds Ratio =1.083; 95% CI: 1.023-1.147; 
p=0.00) were significantly associated.However, hyper-
tension, dyslipidemia and gender did not show such a 
correlation.
Discussion
Coronary artery disease is a main reason for morbidity 
and mortality among patients undergoing elective non-
cardiac surgery; cardiac deaths comprise nearly one-half 
of perioperative deaths.8 Consequently, the preoperative 
identification and determination of the extent of isch-
emic heart disease can be vital for the accurate manage-
ment of patients undergoing non-cardiac surgery in 
order to decrease the likelihood of unfavorable periop-
erative cardiac events.12
Myocardial perfusion imaging seems to be a favorable 
modality for preoperative risk assessment.12,13 For the 
reason that many preoperative individuals are not capa-
ble of exercising, pharmacological MPI, such as dipyrid-
amole, plays an important role in the assessment and risk 
stratification of these patients,8,14, which is well tolerated 
and has few side effects.15,16 The present study verifies 
the previous reports that revealed preoperative MPI to 
be a useful predictor of cardiac events in patients under-
going non-cardiac surgery.12,17 The occurrence of all car-
diac events was 5.5% and the rate of death only 0.79% in 
our study patients. These results are similar to previous 
studies in which the death rate ranged from 0.6% to 
3.6%.12,18
In the present study, the sensitivity and specificity of 
dipyridamole 99mTc-MIBI SPECT were 85.7% and 
81.6%, respectively, for all cardiac events. The negative 
predictive value (NPV) was 98.9%, which means that the 
incidence of perioperative cardiac events is extremely 
low. In contrast, the positive predictive value (PPV) was 
21.4%, for which further correlation with other modali-
ties, such as angiography, is needed. Similar statistical 
parameters were reported in prior studies.8,19-21
Similarly, we found a significantly higher incidence of 
cardiac events (21.4%) in patients with abnormal MPI 
compared with those without. In our study, the preva-
lence of patients with abnormal MPI had a significantly 
greater prevalence of all risk factors than patients with 
normal MPI. In addition, the prevalence of patients with 
cardiac events had a significantly greater prevalence of 
Figure 1. The result of MPI in patients with and without 
cardiac event.
Table 1. Comparison of CAD risk factors in patients according 
to cardiac events and the results of MPI.
Cardiac 
event
Risk factor
No(239) Yes(14) P-value
DM 23  7 <0.001
Dyslipidemia 93  9  0.06
Hypertension 50 10 <0.001
Smoking 82 11 <0.001
Age≥70 years 26  8 <0.001
CAD: coronary artery disease; MPI: myocardial perfusion imaging; DM: 
diabetes mellitus.
Table 2. Comparison of CAD risk factors in patients with and 
without cardiac events.
MPI
Risk factor
Normal 
(197)
Abnormal 
(56)
P value
DM 11 19 <0.001
Dyslipidemia 55 47 <0.001
Hypertension 23 42 <0.001
Smoking 46 47 <0.001
Age≥70 years 22 12  0.04
CAD: coronary artery disease; MPI: myocardial perfusion imaging; DM: 
diabetes mellitus.
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all risk factors, except for dyslipidemia, than patients 
without events.
In the literature, many studies, mostly using thal-
lium-201 as the imaging agent, have suggested that phar-
macologic MPI was helpful for preoperative risk 
assessment in non-cardiac surgery.4,5 Boucher et al., for 
the first time, demonstrated the utility of MPI for preop-
erative cardiac risk assessment with DIP Tl-201 MPI in 
vascular surgeries.22 In one study, Chen et al. showed that 
a reversible defect was helpful for predicting periopera-
tive cardiac events in patients, even in low-risk patients.12
The cardiac event rate was 1% in the 225 subjects with 
a normal dipyridamole 201 Tl MPI, 8% in patients 
with ischemic defects restricted to one vessel, 20% in those 
with ischemia in two vessels and 52% in those with wide-
ranging ischemic changes.23 Brown and Rowan reported 
that the likelihood of a perioperative cardiac event was 1% 
in patients with only one segment with reversible 201 Tl 
defect, 8% in those with four segments involved and 49% 
in those with seven segments with reversible defects.19
In a review article, Yao and Rozanski summed up the 
results of 15 prognostic studies and demonstrated that a 
very low frequency of perioperative cardiac events 
(9/750, 1.2%) existed among patients who had a normal 
201 Tl MPI study, similar to our findings (2/197, 1.01%). 
The frequency of major cardiac events was 15.6% 
(114/730) in patients with reversible defects and 5.1% 
(14/277) in subjects with fixed defects.21
Furthermore, some studies assessed this issue using 
99mTc-sestamibi as the imaging agent. Bry et al. assessed 
the positive predictive value and cost-effectiveness of 
dipyridamole myocardial scintigraphy in 237 patients 
undergoing vascular surgery.24 The large sample-size 
studies using dipyridamole 99mTc-sestamibi SPECT 
MPI before non-vascular surgery were mentioned by 
Stratmann et al.25,26 Cardiac event rates were 4% for a 
normal MPI, 27% for an abnormal MPI, 24% for an 
ischemic defect and 37% for a fixed defect (p<0.01). In 
Hendel et al.’s study, patients with ischemic defects had a 
significantly higher incidence of death or MI than 
patients with other test results (p<0.001).27
On the other hand, our present findings do not match 
with some investigations that showed no relationship 
between ischemic defects and cardiac outcomes.7,28 In 
addition, Davidson et al. tested the prognostic value of 
MPI in candidates for liver transplant. The sensitivity 
and specificity of dipyridamole 201 Tl-SPECT were 37% 
and 63%, respectively. The positive predictive value 
(PPV) and negative predictive value (NPV) of MPI com-
pared with angiography were 22% and 77%, respectively, 
in all patients. The authors concluded that there was a 
low prognostic value of MPI in these patients and further 
imaging modalities, such as angiography, should be 
applied.6 The reasons for this discrepancy lie in the dif-
ferences in the study population, acquisition protocol 
and technical limitations in these studies.18
Furthermore, the current study depicted that patients 
with an abnormal MPI who had a cardiac event were 
older than patients without a cardiac event and neither 
diabetes mellitus, dyslipidemia, hypertension nor smok-
ing were significantly different in the two subgroups.
In a study of more than 1,300 patients, Bai et al. dem-
onstrated that age was an independent predictor of car-
diac events in patients with abnormal SPECT studies, 
but, in individuals with normal MPI, perioperative risk 
was independent of age.29
Currently, the ACC/AHA guidelines recommend 
non-invasive preoperative testing, such as MPI, for the 
evaluation of cardiac function only in high-risk surgical 
procedures.5 The 2009 ACCF/AHA Guideline concluded 
that three factors, including the patient’s specific clinical 
variables, exercise capacity and surgery-specific risk, 
must be assessed to determine the risk of cardiac events.30
There is remarkable indecision regarding the predic-
tive accuracy of non-invasive preoperative cardiac tests 
and the ACC/AHA algorithm for cardiac risk evalua-
tion.31-33
Meanwhile, some new non-invasive modalities have 
been developed for the diagnosis of coronary artery dis-
ease (CAD), including a fast growing multi-detector 
computed tomography (MDCT) technology which pro-
vides rapid and trustworthy contrast-enhanced imaging 
Table 3. Comparison of CAD risk factors in patients with normal and abnormal MPI.
Risk factor Normal MPI (197 cases) Abnormal MPI (56 cases) Total
 Cardiac event Cardiac event  
 No(195) Yes(2) P-value No(44) Yes(12) P-value  
DM 10 1 0.00 13  6 0.18  30
Dyslipidemia 55 0 0.38 38  9 0.34 102
Hypertension 21 2 0.00 34  8 0.45  65
Smoking 45 1 0.37 37 10 0.94  93
Age≥70 years 20 2 0.89  6  6 0.01  34
CAD: coronary artery disease; MPI: myocardial perfusion imaging; DM: diabetes mellitus.
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of coronary arteries and coronary plaque.34 The high 
negative predictive value of this technique can exclude 
the existence of hemodynamically signiﬁcant CAD.34
Coronary computed tomography angiography (CTA) 
seems to be helpful for the management of patients with 
acute chest pain. Other potential usages include preop-
erative risk assessment and evaluation of revasculariza-
tion. It may also provide valuable information for 
short- and long-term risk assessment as well as stratifica-
tion of cardiovascular disorders.35 Like MPI, patients 
with an intermediate pretest likelihood of CAD may 
benefit from coronary CTA.34
In terms of radiation exposure, the mean effective 
dose with CTA, using 64-slice MDCT, is approximately 
11–22 mSv,36 whereas this value for myocardial perfu-
sion imaging with SPECT is about 15–20 mSv.37
In comparison to MPI, coronary CTA directly visual-
izes the atherosclerotic plaques with a short procedure 
and no specific preparation; however, data on clinical 
utility and cost-effectiveness are lacking and this requires 
further investigation.34
Finally, these findings support the claim that preop-
erative dipyridamole 99mTc-MPI SPECT may be use-
ful for predicting perioperative cardiac events in 
patients with non-cardiac surgery, although further 
evidence needs to be found. Also, this study depicted 
that, with the possibility of perioperative cardiac events 
in patients with a higher pretest likelihood of CAD, 
accurate risk stratification of perioperative cardiac 
events is imperative to allocate informed patients and 
to help surgeons, cardiologists and anesthesiologists in 
decision-making.
It should be mentioned that our study has some limi-
tations. We did not perform gated SPECT imaging and 
semi-quantitative SPECT analysis, because these meth-
ods are not routine in our center. The next limitation is 
the lack of precise surgical risk estimation and evaluation 
of cardiac event and MPI in each group.
It is noteworthy that this non-randomized study may 
have selection bias with heterogeneous groups which 
could add some co-founding variables and have an 
impact on the results. Furthermore, some cardiac events 
may occur over a prolonged time course. Although most 
perioperative cardiac events occur during the first three 
days after surgery,38,39 extended monitoring should be 
taken into account in future studies.
Conclusion
Dipyridamole 99m Tc-MIBI myocardial perfusion imag-
ing can accurately detect the preoperative cardiac risk of 
patients undergoing major non-cardiac surgery. Based on 
the findings, the occurrence of perioperative cardiac events 
in patients with abnormal MPI should be considered, espe-
cially in advanced age. However, further well-designed 
investigations that follow patients for a longer period of 
time are needed to evaluate these results.
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